Biomarkers of cognitive decline in Parkinson's disease.
Cognitive impairment is a frequent and devastating non-motor symptom of Parkinson's disease (PD). Impaired cognition has a major impact on either quality of life or mortality in patients with PD. Notably, the rate of cognitive decline and pattern of early cognitive deficits in PD are highly variable between individuals. Given that the underlying mechanisms of cognitive decline or dementia associated with PD remain unclear, there is currently no mechanism-based treatment available. Identification of biological markers, including neuroimaging, biofluids and common genetic variants, that account for the heterogeneity of PD related cognitive decline could provide important insights into the pathological processes that underlie cognitive impairment in PD. These combined biomarker approaches will enable early diagnosis and provide indicators of cognitive progression in PD patients. This review summarizes recent advances in the development of biomarkers for cognitive impairments in PD.
Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Chin-Hsien
CH
Lin
Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan. Electronic address: robinwu@ntu.edu.tw.
Ruey-Meei
RM
Wu
D015415:Biomarkers / Q000378:metabolism; D003072:Cognition Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000378:metabolism*; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000378:metabolism*
D015415:Biomarkers
Biomarkers; Dementia; Genetic variants; Mild cognitive impairment; Parkinson's disease